secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vanda Pharmaceuticals Inc. (VNDA)
CIK:        0001347178
Form:       8-K
Filed at:   2025-05-07T23:59:59+00:00
Accession:  0001628280-25-023154
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vanda Q1 net loss widens to $29.5M; Fanapt sales up 14% but PONVORY down 18%
----------------------------------------------------------------------------

- Net product sales $50.0M (+5% YoY); net loss $29.5M vs $4.1M loss a year ago.
- Diluted EPS -$0.50; loss reflects $15M imsidolimab license fee and higher commercial spend.
- Fanapt sales $23.5M (+14%), HETLIOZ $20.9M (+4%), PONVORY $5.6M (-18%).
- Cash $340.9M; full-year guidance: revenues $210-250M, year-end cash $280-320M.
- Tradipitant NDA PDUFA Dec 30, 2025; Bysanti NDA PDUFA Feb 21, 2026; imsidolimab BLA expected 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347178/000162828025023154/0001628280-25-023154-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347178/000162828025023154/vnda-20250507.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-023154

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer